To recapitulate the decrease in UCP3 levels caused by hyperinsulinemia, insulin resistance and type 2 diabetes, CRISPR-Cas9 genome editing was used to inactivate one copy of the UCP3 gene in Sprague–Dawley rats (ucp3+/−). The gene discussed is UCP3; the disease is Insulin resistance.